xkh001
mAbexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2022 (NCT05128409)
Timeline
Indications
Mechanism of action
- Interleukin-25INHIBITOR
inhibitor - il-25
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07054736 | Phase 2 | Aug 31, 2025 | Beijing Kanova Biopharmaceutical Co., LTD, Peking University |
| NCT07070297 | Phase 1 | Dec 26, 2023 | Beijing Kanova Biopharmaceutical Co., LTD, Zhejiang University |
| NCT05991661 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2023 | Beijing Kanova Biopharmaceutical Co., LTD, Jinlin University |
| NCT05128409 | Phase 1 | Jan 1, 2022 | Beijing Kanova Biopharmaceutical Co., LTD, Frontage Laboratories, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Kanova Biopharmaceutical Co., LTD | For profit | 4 | 4 | 2 | 2022 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Jinlin University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1